Cabazitaxel targets the MPM genes, TUBB1 and TUBA4A, and was effective in treating non-small cell lung cancer (NSCLC) that was resistant to docetaxel, a drug that targets TUBB1 along with other known interactors of MPM genes [37]. This evidence concerns the gene TUBA4A and non-small cell lung carcinoma.